

NOVEN PHARMACEUTICALS INC

Form 8-K

May 06, 2003

**Table of Contents**

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) April 30, 2003

**Noven Pharmaceuticals, Inc.**

11960 S.W. 144th Street, Miami, Florida 33186  
305-253-5099

Incorporated under the laws of the  
**State of Delaware**

Commission File Number  
**0-17254**

I.R.S. Employer Identification Number  
**59-2767632**

---

**TABLE OF CONTENTS**

SIGNATURES

EXHIBIT INDEX

EX-99.1 Press Release dated April 30, 2003

---

**Table of Contents**

**Item 9. Regulation FD Disclosure (information furnished in this Item 9 is furnished under Item 12).**

In accordance with Securities and Exchange Commission Release No. 34-47583, the following information, which is intended to be furnished under Item 12. Results of Operations and Financial Condition, is instead being furnished under Item 9. Regulation FD Disclosure. The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 12 and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

On April 30, 2003, Noven Pharmaceuticals, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2003. The press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVEN PHARMACEUTICALS, INC.

/s/ Jeffrey F. Eisenberg

---

Jeffrey F. Eisenberg  
Vice President, General Counsel and  
Corporate Secretary

Date: May 6, 2003

---

**Table of Contents**

**EXHIBIT INDEX**

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press Release dated April 30, 2003